Medi-Mibi (Technetium (99mtc) Sestamibi)

Technetium (99mTc) Sestamibi emits gamma radiation and is taken up by heart muscle cells in proportion to regional blood flow. After intravenous injection, a gamma camera captures the emitted radiation, producing images that reflect perfusion patterns and highlight areas with reduced blood supply.

The specific activity and volume of Medi-Mibi are determined by the prescribing physician based on the imaging protocol, patient weight, and the equipment used. Dosing is individualized and should follow the radiopharmacy and nuclear medicine guidelines applicable in the treating facility.

The safety of Medi-Mibi in pregnancy and lactation has not been fully established. It should be avoided unless the diagnostic benefit outweighs potential risks. If administered to a nursing mother, a decision about continuing breastfeeding should be made in consultation with the healthcare provider.

To order Medi-Mibi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Medi-Mibi (Technetium 99mTc Sestamibi) offers high‑resolution images, rapid uptake, and relatively low radiation dose compared with thallium‑201 agents. It is widely used for single‑photon emission computed tomography (SPECT) and provides reliable perfusion data, making it a preferred choice for many nuclear cardiology departments.

Medi-Mibi should be stored at ambient temperature, protected from light, and kept in its original sealed container. Avoid exposure to moisture and extreme temperatures. Before use, allow the vial to reach room temperature if it has been stored in a cooler environment.

Medi-Mibi is administered by a single intravenous injection under the supervision of a qualified nuclear medicine professional. The injection is typically performed in a controlled environment, and imaging is started shortly after administration according to the specific cardiac stress protocol.

Serious risks, although rare, include severe allergic reactions (anaphylaxis), significant hypotension, cardiac arrhythmias, and radiation‑induced skin injury at the injection site. Patients should be monitored closely during and after administration, and emergency equipment should be readily available.

Medi-Mibi should not be given to individuals with a known hypersensitivity to technetium‑based radiopharmaceuticals or any of its excipients. It should also be avoided in pregnant women unless absolutely necessary, and used with caution in patients with severe renal impairment or uncontrolled thyroid disorders.